Fidelity International’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $127M | Buy |
3,752,506
+57,872
| +2% | +$1.93M | 0.09% | 212 |
|
|
2026
Q1 | $111M | Buy |
3,694,634
+528,386
| +17% | +$17M | 0.09% | 224 |
|
|
2025
Q4 | $98.8M | Sell |
3,166,248
-667,903
| -17% | -$16.5M | 0.07% | 234 |
|
|
2025
Q3 | $77.4M | Buy |
3,834,151
+74,835
| +2% | +$1.31M | 0.06% | 265 |
|
|
2025
Q2 | $63M | Buy |
3,759,316
+351,453
| +10% | +$5.67M | 0.05% | 296 |
|
|
2025
Q1 | $52.4M | Buy |
3,407,863
+1,879,746
| +123% | +$33.6M | 0.05% | 306 |
|
|
2024
Q4 | $33.7M | Sell |
1,528,117
-79,243
| -5% | -$1.44M | 0.03% | 382 |
|
|
2024
Q3 | $29M | Sell |
1,607,360
-511,636
| -24% | -$8.95M | 0.03% | 411 |
|
|
2024
Q2 | $34.4M | Sell |
2,118,996
-277,587
| -12% | -$4.28M | 0.03% | 379 |
|
|
2024
Q1 | $33.8M | Buy |
2,396,583
+66,488
| +3% | +$838K | 0.03% | 379 |
|
|
2023
Q4 | $24.3M | Buy |
2,330,095
+758,432
| +48% | +$7.08M | 0.03% | 395 |
|
|
2023
Q3 | $16M | Buy |
1,571,663
+658,380
| +72% | +$6.13M | 0.02% | 438 |
|
|
2023
Q2 | $6.88M | Buy |
913,283
+221,298
| +32% | +$1.79M | 0.01% | 530 |
|
|
2023
Q1 | $6.12M | Buy |
691,985
+266,143
| +62% | +$2.63M | 0.01% | 541 |
|
|
2022
Q4 | $3.88M | Buy |
425,842
+78,590
| +23% | +$686K | ﹤0.01% | 606 |
|
|
2022
Q3 | $2.8M | Buy |
347,252
+59,574
| +21% | +$527K | ﹤0.01% | 635 |
|
|
2022
Q2 | $2.16M | Buy |
287,678
+87,509
| +44% | +$762K | ﹤0.01% | 662 |
|
|
2022
Q1 | $1.88M | Buy |
200,169
+115,151
| +135% | +$961K | ﹤0.01% | 689 |
|
|
2021
Q4 | $681K | Sell |
85,018
-1,177
| -1% | -$10.6K | ﹤0.01% | 753 |
|
|
2021
Q3 | $840K | Sell |
86,195
-6,301
| -7% | -$59K | ﹤0.01% | 725 |
|
|
2021
Q2 | $916K | Buy |
92,496
+19,629
| +27% | +$208K | ﹤0.01% | 749 |
|
|
2021
Q1 | $841K | Buy |
72,867
+16,946
| +30% | +$194K | ﹤0.01% | 730 |
|
|
2020
Q4 | $540K | Buy |
55,921
+4,888
| +10% | +$46.8K | ﹤0.01% | 687 |
|
|
2020
Q3 | $460K | Sell |
51,033
-9,076
| -15% | -$96K | ﹤0.01% | 657 |
|
|
2020
Q2 | $742K | Sell |
60,109
-17,200
| -22% | -$195K | ﹤0.01% | 619 |
|
|
2020
Q1 | $695K | Buy |
77,309
+1,810
| +2% | +$18.5K | ﹤0.01% | 617 |
|
|
2019
Q4 | $740K | Buy |
75,499
+7,085
| +10% | +$63.3K | ﹤0.01% | 658 |
|
|
2019
Q3 | $471K | Buy |
68,414
+5,976
| +10% | +$45.8K | ﹤0.01% | 655 |
|
|
2019
Q2 | $577K | Hold |
62,438
| – | – | ﹤0.01% | 656 |
|
|
2019
Q1 | $979K | Buy |
62,438
+62,153
| +21,808% | +$1.1M | ﹤0.01% | 610 |
|
|
2018
Q4 | $4K | Buy |
285
+116
| +69% | +$2.38K | ﹤0.01% | 748 |
|
|
2018
Q3 | $4K | Buy |
+169
| New | +$3.92K | ﹤0.01% | 744 |
|
|
2017
Q3 | – | Sell |
-13,967
| Closed | -$464K | – | 518 |
|
|
2017
Q2 | $464K | Sell |
13,967
-913,846
| -98% | -$28.3M | ﹤0.01% | 501 |
|
|
2017
Q1 | $29.8M | Sell |
927,813
-155,856
| -14% | -$5.32M | 0.08% | 203 |
|
|
2016
Q4 | $39.3M | Buy |
1,083,669
+189,338
| +21% | +$7.56M | 0.12% | 173 |
|
|
2016
Q3 | $41.1M | Sell |
894,331
-1,947
| -0.2% | -$102K | 0.12% | 164 |
|
|
2016
Q2 | $45M | Sell |
896,278
-22,974
| -2% | -$1.22M | 0.14% | 144 |
|
|
2016
Q1 | $49.2M | Buy |
919,252
+164,416
| +22% | +$9.65M | 0.15% | 141 |
|
|
2015
Q4 | $49.5M | Buy |
+754,836
| New | +$46.6M | 0.15% | 144 |
|
|
2014
Q4 | – | Sell |
-70,233
| Closed | -$3.77M | – | 504 |
|
|
2014
Q3 | $3.77M | Sell |
70,233
-427,128
| -86% | -$22.6M | 0.01% | 418 |
|
|
2014
Q2 | $26.1M | Sell |
497,361
-101,235
| -17% | -$5.17M | 0.1% | 207 |
|
|
2014
Q1 | $31.6M | Sell |
598,596
-26,900
| -4% | -$1.24M | 0.11% | 184 |
|
|
2013
Q4 | $25.1M | Buy |
625,496
+265,696
| +74% | +$10.5M | 0.1% | 197 |
|
|
2013
Q3 | $13.6M | Buy |
359,800
+17,100
| +5% | +$667K | 0.07% | 265 |
|
|
2013
Q2 | $13.4M | Buy |
+342,700
| New | +$13.3M | 0.08% | 240 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Fidelity International's TEVA Position: Q2 2026 in Review
Fidelity International increased its Teva Pharmaceuticals (TEVA) stake by 1.6% in Q2 2026, buying an estimated $1.93M and bringing the position to 3,752,506 shares worth $127M. The position accounts for 0.09% of the portfolio, ranked #212.
Fidelity International first reported a position in TEVA in Q2 2013 and has held it in 45 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Fidelity International held 3,752,506 shares of Teva Pharmaceuticals worth $127M as of Q2 2026.
- Fidelity International bought 57,872 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.93M.
- Teva Pharmaceuticals made up 0.09% of Fidelity International's portfolio in Q2 2026, its #212 holding.
- Fidelity International first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.